From Automation to Autonomy: How Agentic AI Is Redefining Biopharma’s Digital Workforce
Contributed Commentary by Tony Clarke, ICON
June 12, 2026 | Biopharma’s relationship with automation has historically been pragmatic and incremental. Robotic process automation, rules‑based workflows, and task‑specific machine‑learning models have been widely deployed to reduce manual effort and accelerate well‑defined tasks. These approaches delivered value, but they remained fundamentally limited: each tool addressed a narrow slice of work, often creating additional handoffs between systems and teams.
Agentic AI represents a departure from this pattern. Rather than focusing on isolated steps, agentic systems are designed to operate across workflows — retrieving information, generating structured content, and executing multi‑step tasks with contextual awareness. This marks a shift from automation toward bounded autonomy, where software agents execute work within clearly defined constraints underpinned by a human-at-the-center oversight.
Technically, agentic AI systems are distinguished by their architecture. A primary workflow objective is broken down into subtasks, which may be handled by multiple agents in parallel allowing organizations to reimagine business processes beyond resource constraints. Each agent operates with access to relevant data, tools, and constraints, while a coordinating layer manages sequencing, error handling, and escalation. Decisions and context windows persist across tasks, improving consistency while preserving traceability and auditability.
Importantly, these systems are designed to surface uncertainty and request human input when confidence thresholds are exceeded. In biopharma, this architecture aligns closely with the realities of scientific and clinical work. Research, development, and regulatory activities rarely follow linear paths. They require constant interpretation, adjustment, and reconciliation across data sources and organisational boundaries. Agentic systems can support this complexity by handling procedural work that would otherwise require extensive manual coordination.
Early use cases are emerging across the sector. In document‑intensive processes, agentic AI can draft structured sections of protocols, analysis reports, or submission documents, allowing experts to focus on review and refinement rather than composition from scratch. In safety and surveillance workflows, agents can coordinate signal detection activities by interrogating multiple datasets and preparing summaries for scientific assessment. In data management contexts, agentic systems can retrieve and align information from disparate repositories, reducing the need for manual “stitching” across platforms.
The key advantage of these approaches is not task completion for its own sake, but workflow cohesion. When agents handle routine coordination, retrieval and execution, scientists and clinician teams are freed to focus on interpretation, decision‑making and accountability. Over time, this shifts the role of AI from a collection of tools to an integrated digital workforce, one that augments expertise without obscuring responsibility.
This has implications not only for efficiency, but for quality and consistency across programmes.
However, the shift from automation to AI also raises new challenges. Agentic systems can behave unpredictably if poorly constrained, particularly in environments with ambiguous objectives or incomplete data. As such, success depends less on algorithmic sophistication than on guardrails, governance, transparency, UX and human oversight. Organizations must define which tasks are appropriate to delegate, how agents should escalate uncertainty, and how outputs are validated.
This places new emphasis on operational literacy within biopharma teams. Scientists and technologists alike must develop skills in directing, supervising, and evaluating agentic systems — not simply using software tools. Clear governance frameworks are essential to prevent opacity, ensure regulatory alignment, and maintain accountability.
The future advantage in biopharma will not come from maximising machine autonomy, but from building co‑intelligent workflows in which human expertise remains firmly at the center. In this model, unified data and AI technologies work in concert to support scientific judgement — organizing information, coordinating execution, and amplifying expert decision‑making. Autonomy is deliberately bounded, accountability remains human, and technology acts as a force multiplier that enables professionals to operate with greater confidence, clarity, and control.
Tony Clarke is the Senior Vice President of Enterprise AI at ICON, where he leads the organisation’s global AI strategy and oversees the development of scalable, secure and impactful AI solutions across clinical research operations. With over 20 years of experience in digital transformation across pharma and biotech, Tony is recognised for advancing AI adoption in regulated environments and accelerating enterprise innovation. He holds advanced certifications in AI, cloud, cybersecurity and data leadership from MIT, Harvard, Dublin City University, University Limerick & University College Cork. He can be reached at [email protected].